SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 6, 2004
SANGUI BIOTECH INTERNATIONAL, INC.
-----------------------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado
--------
(State or other jurisdiction of Incorporation or organization
000-21271 84-1330732
----------------------- ----------
(Commission File Number) (I.R.S. Employer Identification No.)
Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
------------------------------------------------
(Address of principal executive offices)(Zip Code)
011-49-2302-915-204
-------------------
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Item 9. Regulation FD Disclosure
On May 6, 2004 Sangui Biotech International, Inc. (the "Company")
issued a press release announcing that its German subsidiary, Sangui Biotech
GmbH and Mercatura Cosmetics Biotech AG, Achim, Germany, have signed a letter of
intent aiming at marketing "Pure Moisture", an anti-aging nano-formulation
developed by Sangui. Under the proposed agreement Sangui will license to
Mercatura the exclusive right to sell the nano-emulsion in German and
international markets. Mercatura plans to include this product under its
"Wunderkind" brand, jointly marketed by Mercatura and German top designer
Wolfgang Joop. A copy of the press release is furnished as Exhibit 99.2 to this
report.
The information in this Current Report on Form 8-K, including the
exhibit, is furnished under "Item 2. Management's Discussion and Analysis of
Financial Condition" in accordance with SEC Release No. 33-8216. Furthermore,
the information in this Current Report on Form 8-K, including the exhibit, shall
not be deemed to be incorporated by reference into the filings of the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, as amended.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the Undersigned, thereunto duly authorized.
Sangui Biotech International, Inc.
(Registrant)
Date: May 7, 2004 /s/ Wolfgang Barnikol
----------------------------
By: Wolfgang Barnikol
Its: President, CEO and CFO
INDEX TO EXHIBITS
Exhibit Number Exhibit
-------------- -------
99.1 Press Release dated May 6, 2004*
* This exhibit is furnished to, but not filed with, the Commission by inclusion
herein.